SSB
ZYNE

Sandy Spring Bank’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Sandy Spring Bank’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-50
Closed -$1K – 879
2019
Q2 		$1K Buy
+50
New +$577 ﹤0.01% 823

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sandy Spring Bank's ZYNE Position: Q3 2019 in Review

Sandy Spring Bank sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2019, closing a stake of 50 shares — an estimated $1K sold.

Sandy Spring Bank first reported a position in ZYNE in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 84 funds tracked by Wall St. Rank hold ZYNE as of Q3 2019.

  • Sandy Spring Bank reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2019 after selling out during the quarter.
  • Sandy Spring Bank sold 50 Zynerba Pharmaceuticals, Inc shares in Q3 2019, an estimated $1K.
  • Sandy Spring Bank first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2019 and held it in 1 quarter.
  • Sandy Spring Bank's Zynerba Pharmaceuticals, Inc position peaked at $1K in Q2 2019.
  • 84 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2019.

Based on Sandy Spring Bank's 13F filing for Q3 2019, filed 1 Nov 2019.